M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
CHMP backs Camurus' Oczyesa for acromegaly treatment in EU
Biopharmaceutical company Camurus (NASDAQ STO: CAMX) announced on Friday that it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Oczyesa, a long-acting octreotide subcutaneous depot (CAM2029), as maintenance therapy...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search